Type in Medical Technology

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... on Expanding Pipeline of Drugs For People with type 1 Diabetes - NEW YORK, Aug. 5 ... and the largest charitable funder and advocate of type 1 research. "This agreement with GNF ... of basic research into drugs and treatments for type 1 diabetes," said Alan J. Lewis, PhD, President ...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

... on the development of novel therapeutics for type 2 diabetes, cancer, and cardiovascular disease, ... challenge, two key goals in the management of type 2 diabetes. Under the terms of the ... number will rise to 366 million by 2030. type 2 diabetes (formerly called non-insulin-dependent ...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... therapy in development for the treatment of type 1 Gaucher disease. The Company also announced ... dose study of velaglucerase alfa in patients with type 1 Gaucher disease. The primary goal of this study ... appears to be an excellent choice for type 1 Gaucher patients. The prospect of having ...

British Woman Celebrates a Year of Living Cancer-Free

... that TaNK cells could be the key to a new type of advanced cancer therapy. Doctors at the ... of her bone marrow -- the site affected by the type of leukemia she had -- confirmed that the TaNK ... for five weeks because her neutrophils, a type of white blood cell, were dangerously low -- a ...

Diabetes Gene Raises Odds of Lower Birth Weight

... shown to be involved in the development of type 2 diabetes also predisposes children to having a ... of both lower birth weight and the development of type 2 diabetes in later life." type 2 diabetes occurs either when the pancreas ...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

... Risk in New Antidiabetic Therapies to Treat type 2 Diabetes," the amount of existing alogliptin ... blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... once-daily doses of Lantus in 467 patients with type 2 diabetes taking stable doses of metformin alone ... superiority study included 467 subjects with type 2 diabetes who were not achieving adequate ... 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... who carry none. AF is the most common type of cardiac arrhythmia, and is a major risk factor ... laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation ... prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

... through a catheter can be used to treat a common type of irregular heartbeat, but little is known about ... radiofrequency catheter ablation to treat a type of irregular heartbeat known as atrial ... Atrial fibrillation, the most common type of irregular heartbeat in adults, affects more ...

Spherix Announces Positive Phase 2 Study Results

... (D-tagatose), in the treatment and management of type 2 diabetes. The Phase 2 trial is expected to be ... be a valuable treatment option for patients with type 2 diabetes," said Dr. Claire Kruger, CEO of ... 6 months in reducing HbA1c, a key indicator of type 2 diabetes that monitors glycated hemoglobin in ...

Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs

... to the FDA to begin clinical trials in SMA type I. It is the intent of CSC to gain approval to ... development of a cell replacement therapy for SMA type I. Numerous pre-clinical efficacy studies ... to begin a Phase I/IIA clinical trial in SMA type I." Tetracycline Program: According to ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... the treatment of individuals with recent-onset type 1 diabetes. The PROTEGE trial is a ... of teplizumab in individuals with recent-onset type 1 diabetes, aged 8 to 35, who are within 12 weeks ... important milestone for MacroGenics and for the type 1 diabetes research community," stated Scott ...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

... safety of NT-201 (Xeomin(R); botulinum neurotoxin type A free from complexing proteins) in pre-treated ... safety of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in ... of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in upper limb ...

The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide

... which is under investigation as a treatment for type 2 diabetes, to exenatide, the currently marketed ... meaningful treatment advance for patients with type 2 diabetes." LEAD(TM) 6 was a randomized, ... (-1.61 mmol/L vs -0.60 mmol/L) in this typical type 2 diabetes population. The study comprised 464 ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... (FDA's) guidance for evaluating CV risk in type 2 diabetes agents. These findings were presented ... 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause ... treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent ...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

... Antigen-Specific and Non-Specific Regulation of type 1 Diabetes. In the session, Dr. Devangi Mehta, ... monoclonal antibody, in new onset autoimmune type 1 diabetes patients. About the DEFEND ... age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at ...

Research: Popular Diabetes Medications Associated with Increase in Bone Fractures

... Health Sciences Center found that patients with type 2 diabetes taking a thiazolidinedione (TZD) to ... 43 percent higher incidence of bone fracture than type 2 diabetes patients not taking TZDs. TZDs -- a ... and July 2008 of 144,399 patients age 43-63 with type 2 diabetes. The study sample consisted of 69,047 ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... once weekly, an investigational therapy for type 2 diabetes. These findings were presented at the ... important unmet need for treating patients with type 2 diabetes with just one dose per week." ... 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause ...

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162

... "Even with available treatments, many type 2 diabetes patients still struggle to control ... treatments lead to weight gain, a concern for type 2 diabetes patients, most of whom are already ... glimepiride (8 mg, once daily) in patients with type 2 diabetes. Patients were treated previously ...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

... in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) ... Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 ... diabetes therapies, over half of patients with type 2 diabetes are unable to achieve the ADA target ...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

... may be a promising new therapy for patients with type 1 and type 2 diabetes, as it controls post meal-time glucose ... the AFRESA Inhaler for use in adult patients with type 1 ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

... subcutaneously once-weekly for the treatment of type 2 diabetes. These data will be presented as part ... Phase II study of LY2189265, 262 patients with type 2 diabetes who were suboptimally controlled on at ... treatment option for the millions of people with type 2 diabetes." About LY2189265 LY2189265, ...

Boehringer Ingelheim Unveils Diabetes Pipeline

... compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is ... of blood sugar, when given as add-on therapy to type 2 diabetes patients inadequately controlled on ... potential of linagliptin for the treatment of type 2 diabetes." DPP-4 inhibitors are a newer ...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

... the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of ... (PFTs) over a 2-year period in subjects with type 1 and 2 diabetes mellitus receiving AFRESA ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... insulin resistance, an underlying cause of type 2 diabetes. This helps the body respond better to ... to improve glycaemic control in patients with type 2 diabetes mellitus. More than 18 million Americans have type 2 diabetes, making it the most common form of ...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

... in targeted number of almost 2,500 subjects with type 2 diabetes, whose blood sugar level is ... IV (DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms ... alogliptin/ACTOS targets the core defects of type 2 diabetes - insulin resistance (when the body ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

... indicated in combination with cisplatin (another type of chemotherapy) for the first-line treatment of ... in combination with carboplatin (another type of chemotherapy) for the patient with ovarian ... patients previously treated with 5-FU (another type of chemotherapy). GEMZAR in combination with ...

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women

... the gene signatures identified by the Onco type DX(R) breast cancer test in a large number of ... and results support the clinical utility of Onco type DX in providing quantitative information to help ... cancer patient from Baltimore. "After my Onco type DX test results came back and I discussed them ...

Type 2 Diabetes: An Epidemic Among America's Youth

... -- With the number of children suffering from type 2 diabetes growing at an alarming rate, ... to have led to the epidemic of children with type 2 diabetes." The National Institutes of ... in order to identify the children at risk for type 2 diabetes and to demonstrate the effectiveness ...

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient

... . The magazine features medical information on type 1 and type 2 diabetes, diabetes complications, and tips on ... which leaves them at risk for developing type 2 diabetes and cardiovascular complications. To ...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

... and the largest charitable funder and advocate of type 1 research, will host its 27th Annual Hearts ... $1.5 million for research to find a cure for type 1 diabetes and its complications. Insulet ... of the Special Statutory Funding Program for type 1 diabetes research. Previous funding through ...

Spherix Reports First Quarter 2009 Earnings

... trial investigating efficacy as a treatment for type 2 diabetes ongoing: Interim data ... efficacy of Naturlose as a novel treatment for type 2 diabetes." Financial Results for the ... to the efficacy of Naturlose as a treatment for type 2 diabetes. About Spherix Spherix ...

TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry

... infection Implant type implants infections rate implants ... infection Implant type implants infections rate implants ... infection Implant type implants infections rate implants ...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

... weight. Complications from the leading type 2 diabetic therapies include weight gain and ... improved safety profile for individuals with type 2 diabetes. If the results of this study can be ... much of their careers working on treatments for type 2 diabetes. Colca also was instrumental in the ...

Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus

... of countries is a subtype of Influenza virus type A. The new Focus Diagnostics test simultaneously ... laboratories to provide positive Influenza virus type A positive specimens to public health authorities ... that are found to be positive for Influenza virus type A through testing performed by a Quest ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... Prevents Onset of Early Kidney Disease in type 2 Diabetes Patients SAN FRANCISCO, May 8 ... the onset of microalbuminuria in patients with type 2 diabetes (T2DM). Microalbuminuria is an early ... for about 90 percent of diabetes cases worldwide, type 2 diabetes results from the body's inability to ...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

... Blacks (20.7/11 mm Hg) and patients with type 2 diabetes (21.5/12.6 mm Hg). AZTEC was the ... patient populations, such as patients with type 2 diabetes and Blacks." During the study, ... Black and 43 patients were diagnosed as having type 2 diabetes (populations are not mutually ...

Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity

... such as hypertension, dyslipidemia and type 2 diabetes. The co-primary endpoints for these ... is an obesity therapy being developed to address type 2 diabetes as well as weight loss. In phase 2 and ... phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS ...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

... and in many countries worldwide for people with type 2 diabetes who are unable to achieve good ... to enhance the user experience for patients with type 2 diabetes," said Vince Mihalik, senior vice ... in both healthy volunteers and people with type 2 diabetes. The study will also evaluate efficacy ...

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

... delivery of exenatide for the treatment of type 2 diabetes HAYWARD, Calif., April 24 ... and involves the treatment of 44 patients with type 2 diabetes for a period of 4 weeks. (Logo: ... as a twice-daily self-injection therapy for type 2 diabetes. Intarcia's phase 1 study is ...